Arrowhead Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Did you know?
ARWR's revenue grew at a 30.4% CAGR over the last 6 years.
Current Price
—
Profile
Valuation (TTM)
Market Cap—
P/E—
EV—
P/B—
Shares Out—
P/Sales—
Revenue—
EV/EBITDA—
Arrowhead Pharmaceuticals Inc (ARWR) Stock Analysis
Market Cap—
Current Price—
P/E Ratio—
Forward P/E—
PEG Ratio—
EPS—
Book Value—
P/B Ratio—
ARWR Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use -0.4% FCF growth (CAGR)
Cash vs Debt
Net Debt: 507M
Revenue
169M
FY19
88M
FY20
138M
FY21
243M
FY22
241M
FY23
4M
FY24
829M
FY25
Net Income
68M
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Did you know?
ARWR's revenue grew at a 30.4% CAGR over the last 6 years.
Arrowhead Pharmaceuticals Inc (ARWR) Financial Summary
Arrowhead Pharmaceuticals Inc (ARWR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ..
..
ARWR Key Financial Metrics
| Metric | Value |
|---|
ARWR Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $168.80M | $67.97M |
| FY20 | $87.99M | $-84.55M |
| FY21 | $138.29M | $-140.85M |
| FY22 | $243.23M | $-176.06M |
| FY23 | $240.74M | $-205.28M |
| FY24 | $3.55M | $-599.49M |
| FY25 | $829.45M | $-1.63M |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.